United States
PanOptica, Inc., founded in 2009 and headquartered in the United States, is a pioneering company in the field of ophthalmic therapeutics. With a powerful slogan, "Empowering vision restoration through groundbreaking ophthalmic therapeutics," the company is dedicated to enhancing the quality of life for patients with common eye diseases who suffer severe vision loss despite existing treatments.
Recognizing the crucial role of vision and the challenges faced by eye care professionals, PanOptica seeks to license and develop innovative therapies. Their flagship development, PAN-90806, a novel small-molecule selective VEGF receptor antagonist, holds promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.
Their efforts attracted significant attention and a $11.00M Series B investment in 2017 from reputable investors SV Health Investors and Third Rock Ventures. This financial backing underscores their potential to revolutionize treatments for sight-threatening conditions.
